Sorted By Test Name - Mayo Medical Laboratories

PCPRO
61654
therefore, is an adverse prognostic indicator. Flow cytometric immunophenotyping (FCIP) is a recognized
method for detecting plasma cell Ig light chain restriction. However, shortcomings of this technique, as
traditionally performed, include its relative insensitivity and its consistent underestimation of the number
of clonal plasma cells present. Both of these short-comings are likely attributable to limitations of the
instruments and antibodies used, as well as the presence of intraclonal phenotypic heterogeneity, which
created difficulties in accurately detecting and enumerating all of the clonal plasma cells. For this reason,
the FCIP plasma cell clonality assessment previously performed in our laboratory was supplemented with
a slide-based immunofluorescence technique. However, recent advances in flow cytometry have led to the
development of more powerful instruments and antibody reagents that allow for the use of greater
antibody combinations and increased resolution of the data. With these tools, the ability of FCIP to detect
and enumerate plasma cell clones has been greatly enhanced, allowing us to discontinue the supplemental,
labor-intensive, slide-based plasma cell evaluation in peripheral blood specimens. See Laboratory
Screening Tests for Suspected Multiple Myeloma in Special Instructions and the Laboratory Approach to
the Diagnosis of Amyloidosis algorithm in Special Instructions. Also see Diagnosis and Monitoring of
Multiple Myeloma in Publications.
Useful For: Detecting peripheral blood involvement by plasma cell proliferative disorders Establishing
the diagnosis of and determining prognosis for plasma cell proliferative disorders
Interpretation: In normal peripheral blood specimens, no clonal plasma cells are present (polytypic or
too few to detect). Plasma cells are CD38 and CD138 positive. Normal (polyclonal, nonneoplastic)
plasma cells are typically CD19-positive, whereas neoplastic (clonal) plasma cells typically are
CD19-negative. CD19 expression is especially helpful in distinguishing clonal from nonclonal plasma
cells when few analyzable cells are present. CD45 may be expressed by both normal and neoplastic
plasma cells. In some plasma cell proliferative disorders there are both CD45-positive and CD45-negative
subsets within the clonal cell population. The evaluation of these antigens aids in the identification of
abnormal plasma cells, however, they will not be reported independently.
Reference Values:
CD38+/CD138+ plasma cells=0.0
Clinical References: Nowakowski GS, Witzig TE, Dingli D, et al: Circulating plasma cells detected
by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.
Blood 2006;106(7):2276-2279
Plasma Cell DNA Content and Proliferation, Bone Marrow
Clinical Information: Plasma cell proliferative disorders are a group of plasma cell derived clonal
hematologic neoplasms which exhibit a wide range of biologic activity ranging from monoclonal
gammopathy of uncertain significance (MGUS), a usually indolent disorder with a low rate of disease
progression, to multiple myeloma (MM), a disease that is often aggressive with poor long-term survival.
Detecting plasma cell clonality through demonstrating immunoglobulin (Ig) light chain restriction (ie, the
presence of either predominately kappa or predominately lambda light chains), supplemented by the
plasma cell immunophenotype and DNA index, is an important element in establishing the diagnosis. It is
important to correctly classify patients with plasma cell proliferative disorders as the various disease
entities are treated differently. A number of factors are used for this classification including the proportion
clonal bone marrow plasma cells, the DNA index of the clonal plasma cells, and their proliferative
activity. The plasma cell DNA index and proliferation assessment by flow cytometry are rapid and
reliable. This information can be used to distinguish patients with overt, active MM from less aggressive
diseases such as MGUS and smoldering MM. Furthermore, in combination with other laboratory data, the
results of these studies can be used to as a measure of disease aggressiveness in newly diagnosed MM and
also to determine therapeutic efficacy and detect disease relapse in treated MM patients. See Laboratory
Screening Tests for Suspected Multiple Myeloma in Special Instructions. Also see Diagnosis and
Monitoring of Multiple Myeloma in Publications.
Useful For: Establishing a diagnosis of a plasma cell proliferative disorder Providing prognostic
information for newly diagnosed multiple myeloma and other plasma cell proliferative disorders
Assessing response to therapy and detecting disease relapse and progression in treated plasma cell
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1426